Mesoblast Limited (LWB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mesoblast Limited (LWB) has a cash flow conversion efficiency ratio of -0.032x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-16.28 Million ≈ $-19.03 Million USD) by net assets (€501.84 Million ≈ $586.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LWB market cap overview for the company's overall valuation and market capitalisation.
Mesoblast Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Mesoblast Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mesoblast Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mesoblast Limited ranked by their cash flow conversion efficiency. Explore Mesoblast Limited (LWB) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dongfeng Automobile Co Ltd
SHG:600006
|
0.072x |
|
Odontoprev S.A
SA:ODPV3
|
0.005x |
|
Bonesupport Holding AB
ST:BONEX
|
0.085x |
|
Essity AB (publ)
ST:ESSITY-A
|
0.033x |
|
Metrics Master Income Trust
AU:MXT
|
0.036x |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
-0.028x |
|
Hangzhou Shunwang Tech
SHE:300113
|
0.044x |
|
Permian Basin Royalty Trust
NYSE:PBT
|
88.414x |
Annual Cash Flow Conversion Efficiency for Mesoblast Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of Mesoblast Limited from 2014 to 2025. View LWB live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | €597.44 Million ≈ $698.47 Million |
€-49.95 Million ≈ $-58.40 Million |
-0.084x | +17.12% |
| 2024-06-30 | €480.36 Million ≈ $561.59 Million |
€-48.46 Million ≈ $-56.65 Million |
-0.101x | +19.98% |
| 2023-06-30 | €501.84 Million ≈ $586.70 Million |
€-63.27 Million ≈ $-73.97 Million |
-0.126x | +4.74% |
| 2022-06-30 | €497.04 Million ≈ $581.10 Million |
€-65.78 Million ≈ $-76.91 Million |
-0.132x | +23.63% |
| 2021-06-30 | €581.40 Million ≈ $679.71 Million |
€-100.75 Million ≈ $-117.79 Million |
-0.173x | -68.88% |
| 2020-06-30 | €549.33 Million ≈ $642.22 Million |
€-56.37 Million ≈ $-65.90 Million |
-0.103x | +14.59% |
| 2019-06-30 | €481.05 Million ≈ $562.40 Million |
€-57.79 Million ≈ $-67.56 Million |
-0.120x | +12.56% |
| 2018-06-30 | €546.01 Million ≈ $638.34 Million |
€-75.01 Million ≈ $-87.70 Million |
-0.137x | +25.64% |
| 2017-06-30 | €516.77 Million ≈ $604.15 Million |
€-95.47 Million ≈ $-111.62 Million |
-0.185x | -10.89% |
| 2016-06-30 | €528.16 Million ≈ $617.48 Million |
€-88.00 Million ≈ $-102.88 Million |
-0.167x | +22.83% |
| 2015-06-30 | €467.99 Million ≈ $547.13 Million |
€-101.04 Million ≈ $-118.12 Million |
-0.216x | -55.40% |
| 2014-06-30 | €539.18 Million ≈ $630.36 Million |
€-74.91 Million ≈ $-87.57 Million |
-0.139x | -- |
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more